https://scholars.lib.ntu.edu.tw/handle/123456789/581878
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | JIA-HORNG KAO | en_US |
dc.contributor.author | Ahn S.H. | en_US |
dc.contributor.author | Chien R.-N. | en_US |
dc.contributor.author | Cho M. | en_US |
dc.contributor.author | Chuang W.-L. | en_US |
dc.contributor.author | Jeong S.-H. | en_US |
dc.contributor.author | CHEN-HUA LIU | en_US |
dc.contributor.author | Paik S.-W. | en_US |
dc.date.accessioned | 2021-09-04T06:11:02Z | - |
dc.date.available | 2021-09-04T06:11:02Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85018691362&doi=10.1111%2fjgh.13709&partnerID=40&md5=352088b171ad46e3ebecd35328342738 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/581878 | - |
dc.description.abstract | Chronic hepatitis C (CHC) infection poses a global healthcare burden, being associated with serious complications if untreated. The prevalence of hepatitis C virus (HCV) infection is highest in areas of Central, South, and East Asia; over 50% of HCV patients worldwide live in the region, where HCV genotypes 1b, 2, 3, and 6 are the most prevalent. Treatment outcomes for chronic hepatitis C vary by ethnicity, and Asian patients achieve higher sustained virologic response rates following interferon (IFN)-based therapy than non-Asians. However, low efficacy, poor safety profile, and subcutaneous administration limit the use of IFN-based therapies. Superior virologic outcomes have been observed with different classes of direct-acting antivirals (DAAs) alone or in combination, and several all-oral DAA regimens are available in Asia. These regimens have shown excellent efficacy and favorable tolerability in clinical trials, yet there is a need for further studies of DAAs in a real world context, particularly in Asia. Furthermore, IFN-free treatment may not be accessible for many patients in the region, and IFN-based regimens remain an option in some countries. There is a need to improve current clinical practices for HCV management in Asia, including effective screening, disease awareness, and prevention programs, and to further understand the cost-effectiveness of IFN-free regimens. The evolution of potent treatments makes HCV eradication a possibility that should be available to all patients. However, access to these therapies in Asian countries has been slow, primarily because of economic barriers that continue to present a hurdle to optimal treatment. ? 2016 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd | - |
dc.publisher | Blackwell Publishing | - |
dc.relation.ispartof | Journal of Gastroenterology and Hepatology (Australia) | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | antivirus agent; antivirus agent; interferon; antiviral therapy; Asia; Asian; chronic hepatitis C; clinical practice; emergency treatment; Hepatitis C virus; human; nonhuman; prevalence; priority journal; Review; treatment outcome; Asia; economics; genetics; genotype; health care cost; Hepacivirus; Hepatitis C, Chronic; Antiviral Agents; Asia; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Prevalence | - |
dc.title | Urgency to treat patients with chronic hepatitis C in Asia | en_US |
dc.type | Review | en |
dc.identifier.doi | 10.1111/jgh.13709 | - |
dc.identifier.pmid | 28005275 | - |
dc.identifier.scopus | 2-s2.0-85018691362 | - |
dc.relation.pages | 966-974 | - |
dc.relation.journalvolume | 32 | - |
dc.relation.journalissue | 5 | - |
item.openairetype | Review | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0002-2442-7952 | - |
crisitem.author.orcid | 0000-0003-3622-9707 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。